GCI’s healthcare arm has picked up the pounds 200,000 fee account
for a new diabetes treatment from pharmaceutical firm Novo Nordisk, the
world’s leading producer of insulin.
The new product, repaglinide, is a treatment for the management of
non-insulin dependent diabetes. GCI won the account following a two-way
competitive pitch against Shire Hall.
’We will conduct a pre-launch and launch programme for the next 18
months,’ said GCI healthcare director Catherine Warne.
The win also includes Novo Nordisk’s existing portfolio of insulin
products, which include injection and monitoring systems for diabetes
care. The products were previously handled for six years by Lowe Fusion
(formerly Fusion), which declined to repitch for the business.
Non-insulin dependent diabetes occurs when the pancreas becomes unable
to produce sufficient insulin to regulate blood glucose effectively. It
is considered to be the rising form of diabetes in developed countries,
where ageing populations and obesity contribute to an increasing
Novo Nordisk was formed by the merger in 1989 of Danish insulin
producers Novo and Nordisk. As well as diabetes treatments, the company
produces drugs for the treatment of depression and haemophilia.